Episode 9 tells the medicinal-chemistry redemption arc: how chemists tried to retain ibogaines therapeutic core while deleting cardiotoxicity and the multi-hour hallucinogenic experience. 18-methoxycoronaridine (18-MC) is presented as a selective α3β4 antagonist that sidesteps hERG and serotonergic hallucinogenic activity. Tabernanthalog, the function-oriented simplification from the Olson lab, is examined in detail — including its non-hallucinogenic, non-cardiotoxic profile, rodent efficacy for alcohol- and heroin-seeking, and clinical progression under Delix Therapeutics. The psychoplastogen thesis (the argument that the therapeutic effect may be separable from the psychedelic experience) is presented with its scientific pushback. SAR lessons and other ibogalogs (DemeRx/atai programs, noribogaine studies) are covered, with accurate pipeline sta ...